Brief: Nurix Therapeutics Intends To Advance Nx-5948 Into Pivotal Trial In 2025

Nurix Therapeutics

16/06/2024 10:35

June 16 (Reuters) - Nurix Therapeutics Inc  NRIX.O :
    * NURIX THERAPEUTICS PRESENTS POSITIVE RESULTS FROM ONGOING
CLINICAL TRIAL OF NX-5948 IN PATIENTS WITH RELAPSED REFRACTORY
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AT THE EUROPEAN HEMATOLOGY
ASSOCIATION CONGRESS (EHA2024)
    * NURIX THERAPEUTICS INC - NURIX INTENDS TO ADVANCE NX-5948
INTO
PIVOTAL TRIAL(S) IN 2025
    * NURIX THERAPEUTICS INC - CLINICAL RESPONSES IN CLL
PATIENTS WERE
RAPID AND DEEPENING WITH LONGER TIME ON TREATMENT
    * NURIX THERAPEUTICS-RESPONSE RATE OF 69.2% OBSERVED IN
HEAVILY
PRETREATED PATIENT POPULATION INCLUDING PATIENTS WITH BTK
INHIBITOR RESISTANCE MUTATIONS

Source text for Eikon:  ID:nGNX5SwcxW 
Further company coverage:  NRIX.O 

 ((Reuters.Briefs@thomsonreuters.com;))